Approved indications
Ozempic is approved for adults with type 2 diabetes to improve blood sugar control, to reduce the risk of major cardiovascular events (such as heart attack, stroke, or cardiovascular death) in those with established heart disease, and to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in those with chronic kidney disease.

Common off-label uses
Clinicians often prescribe Ozempic off label for weight loss in people with obesity or overweight, with or without diabetes, based on strong semaglutide data from diabetes and obesity trials; however, the obesity-specific brand Wegovy is the product FDA-approved for chronic weight management, so evidence for Ozempic in people without diabetes is extrapolated rather than label-based. Other emerging off-label uses (such as for fatty liver disease or polycystic ovary syndrome) are under study and currently supported only by limited or early data.

Efficacy expectations
Many people see lower fasting blood sugar and fewer post-meal spikes within the first few weeks, with full A1C reduction (often around 1–1.5 percentage points) developing over about 3 months at a stable dose. Weight loss typically builds gradually, with average losses of roughly 5–10% of body weight over 6–12 months in people with type 2 diabetes, especially at higher doses and with diet and activity changes. Compared with many other glucose-lowering drugs and earlier GLP-1 receptor agonists, Ozempic generally produces greater improvements in A1C, more weight loss, and proven cardiovascular and kidney risk reduction when taken long term.

Typical dosing and how to use
Ozempic is given as a subcutaneous injection once weekly on the same day each week, at any time of day, with or without food, into the abdomen, thigh, or upper arm (rotating sites each time). The usual schedule is 0.25 mg once weekly for 4 weeks (to help the body adjust), then 0.5 mg once weekly; if more effect is needed, the dose may be increased after at least 4 weeks at each level to 1 mg once weekly and, if required, up to a maximum of 2 mg once weekly as prescribed.

• Use only the pen that matches your prescribed dose, follow the pen’s Instructions for Use step by step, and always attach a new needle for each injection.
• Ozempic can be used with other diabetes medicines, but doses of insulin or sulfonylureas may need lowering to reduce hypoglycemia risk.

Special dosing instructions
If needed, the weekly injection day can be changed as long as there are at least 2 days (more than 48 hours) between doses. Do not share your pen with anyone else, even if the needle is changed.

Missed dose guidance
If you miss a dose and less than 5 days have passed, take the missed dose as soon as you remember and then continue your usual weekly schedule. If more than 5 days have passed, skip the missed dose and take your next dose on the regularly scheduled day; do not take two doses at once or on the same day.

Overdose
Taking more Ozempic than prescribed can cause severe nausea, vomiting, or low blood sugar, particularly if you also use insulin or sulfonylureas. In case of suspected overdose, contact your prescriber, local poison control center, or emergency services immediately; medical staff can provide monitoring and supportive care as needed.

Common side effects
The most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, stomach pain, and constipation; they are very frequent, especially when starting or increasing the dose, are usually mild to moderate, and often improve over time. Some people also report decreased appetite, indigestion, fatigue, or mild injection-site reactions.

• To lessen stomach symptoms, dose is increased gradually and taking injections on the same day each week, eating smaller meals, and avoiding heavy, high-fat meals can help.
• If vomiting, diarrhea, or poor intake are severe or persistent, dehydration and kidney problems can occur and medical review is needed.

Serious or rare adverse effects
Seek immediate medical attention for possible pancreatitis (sudden severe abdominal pain with or without vomiting), gallbladder problems (upper abdominal pain, fever, yellowing of skin or eyes, pale stools), severe allergic reactions (swelling of face, lips, tongue or throat, trouble breathing, severe rash, faintness), signs of severe dehydration (little or no urine, dizziness, confusion), or symptoms suggestive of thyroid tumor (neck lump, hoarseness, trouble swallowing or breathing). Worsening diabetic retinopathy (sudden vision changes) has been seen in some people with pre-existing eye disease when blood sugar improves quickly and also needs prompt eye evaluation.

Warnings and precautions
Ozempic carries a boxed warning for thyroid C-cell tumors and must not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2). It is not recommended for people with a history of pancreatitis unless the benefits clearly outweigh the risks, and caution is needed in those with severe stomach motility problems (such as gastroparesis). The drug is not approved for children; its safety and effectiveness in people under 18 years are not established. In pregnancy, Ozempic should generally be avoided, and the manufacturer advises stopping it at least 2 months before a planned pregnancy; its effects during breastfeeding are unknown, so use requires careful risk–benefit discussion.

• Use with insulin or sulfonylurea medicines can increase the risk of low blood sugar, so those doses may need adjustment and closer monitoring.
• People with kidney disease can use Ozempic, and it may protect kidney function, but severe vomiting or diarrhea can acutely worsen kidney function, so kidney tests and hydration are important.

Overall safety profile
Compared with many older diabetes medicines, Ozempic has a low risk of hypoglycemia when used without insulin or sulfonylureas and offers cardiovascular and kidney benefits, but gastrointestinal side effects are more frequent and some people need to stop because of them. Long-term surveillance continues to monitor for rare risks such as pancreatitis or possible thyroid tumors, as with other GLP-1 receptor agonists.

Reporting side effects and safety updates
Patients should inform their prescriber or pharmacist about any side effects and can report serious or unexpected reactions to the FDA’s MedWatch program (online or by calling 1-800-FDA-1088). Up-to-date safety communications are available from the FDA and from the Ozempic manufacturer’s patient and professional websites.

Prescription and OTC medicines
Ozempic is often combined safely with other diabetes drugs, but using it with insulin or sulfonylureas increases the risk of low blood sugar, so those doses may need reduction and closer glucose monitoring. Because Ozempic slows stomach emptying, it may delay absorption of some oral medicines (such as pain relievers like acetaminophen or ibuprofen, or blood thinners like warfarin), so prescribers may monitor certain drugs more closely, for example with extra INR checks for people on warfarin after starting or changing the Ozempic dose.

Supplements, foods, and alcohol
No specific food restrictions are required with Ozempic injections, and it can be taken with or without meals, but large, high-fat meals can worsen nausea. Most vitamins and common supplements do not have known direct interactions, yet it is important to review them with a clinician because slowed gastric emptying could affect how some products are absorbed. Moderate alcohol intake may be acceptable for many adults, but heavy drinking increases the risks of pancreatitis and low blood sugar, so alcohol use should be discussed with the prescriber.

Medical conditions and co-medications requiring caution
Ozempic should not be used in anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2, and it is generally avoided in people with prior pancreatitis or severe gastroparesis. Extra care and monitoring are needed in people with significant diabetic retinopathy, chronic kidney disease (especially if they develop severe vomiting or diarrhea), or those on weight-based or narrow-therapeutic-index medications whose dosing might be affected by weight loss or altered drug absorption.

Procedures, imaging, and monitoring needs
Because Ozempic slows stomach emptying, it may increase the risk of food remaining in the stomach during procedures that use anesthesia or deep sedation, so patients should always tell surgeons and anesthesiologists they are using a GLP-1 medicine; the care team may advise holding doses before certain procedures. Routine care usually includes periodic checks of A1C, blood glucose, kidney function, weight, and sometimes eye exams for diabetic retinopathy, with additional tests ordered if symptoms suggest pancreatitis, gallbladder problems, or other complications.

Q: Can I use Ozempic just for weight loss if I do not have diabetes?
A: Ozempic is approved only for type 2 diabetes and related heart and kidney risk reduction, but many clinicians prescribe it off label for weight loss; for people without diabetes, the similar medicine Wegovy is the product specifically approved for chronic weight management.

Q: How soon will I notice results from Ozempic?
A: Some people see lower blood sugar and reduced appetite within a few weeks, but the full effects on A1C and weight typically build gradually over 3–6 months after reaching a stable maintenance dose.

Q: Do I have to stay on Ozempic long term?
A: Ozempic is generally intended as a long-term treatment for type 2 diabetes and cardiovascular or kidney risk reduction, and blood sugar and weight often drift back toward baseline if the medication is stopped without another effective plan.

Q: What is the difference between Ozempic and Wegovy?
A: Both contain semaglutide, but Ozempic is dosed and approved for type 2 diabetes (and cardiorenal risk reduction), while Wegovy uses higher doses and is approved specifically for chronic weight management and certain heart-related risk reduction in people with obesity or overweight.

Q: Can I drink alcohol while taking Ozempic?
A: Limited to moderate alcohol intake may be acceptable for many adults, but heavy drinking can raise the risk of pancreatitis and low blood sugar, so alcohol use should be discussed with your clinician and kept within recommended limits.

Q: What should I do if Ozempic upsets my stomach?
A: Nausea or other stomach symptoms are common when starting or increasing the dose, and they often improve with smaller, low-fat meals and time; if symptoms are severe, persistent, or include intense abdominal pain, contact your prescriber promptly.

Storage
Before first use, keep Ozempic pens in the refrigerator at 36°F to 46°F (2°C to 8°C), protected from light and never frozen; after first use, a pen can be stored either refrigerated or at room temperature 59°F to 86°F (15°C to 30°C) for up to 56 days with the cap on. Do not use a pen that has been frozen, overheated, or shows cloudy, discolored, or particulate solution, and always keep pens out of reach of children and pets.

Disposal
Throw away each Ozempic pen 56 days after first use, even if it still contains medicine, and place used pens and needles in a puncture-resistant sharps container rather than household trash or recycling. Follow your local or pharmacy guidance for sharps disposal programs, and never share or reuse needles or pens between people.